Type of security: Stock
Sector: Health Care
Industry: Major Pharmaceuticals
Market Capitalization: 554.46 M
The data is delayed by 15 minutes.
Description: Epizyme, Inc., a clinical stage biopharmaceutical company, discovers and develops personalized therapeutics for patients with genetically defined cancers. It identifies the genetic alterations that create cancer causing genes, known as oncogenes; selects patients in whom the identified genetic alteration is found; and designs small molecule therapeutic product candidates to inhibit the oncogene. The company has two histone methyltransferases (HMT) inhibitors in clinical development for the treatment of patients with genetically defined cancers. It is conducting a Phase I clinical trial of its product candidate, EPZ-5676, an inhibitor targeting the DOT1L HMT for the treatment of acute leukemias with genetic alterations of the MLL gene; and a Phase I/II clinical trial of another product candidate, EPZ-6438, an inhibitor targeting the EZH2 HMT for the treatment of a genetically defined subtype of non-Hodgkin lymphoma and solid tumors, including INI1-deficient tumors, such as synovial sarcoma and malignant rhabdo
|Shares Outstanding||57.22 M||EPS||EPS Growth - 4 Quarters||EPS Growth - Q/Q|
|EPS Growth - Y/Y||Sales Growth - 4 Quarters||-90.4%||Sales Growth - Q/Q||-91.2%||P/E|
|P/E To EPS Growth||P/S||19.17||P/BV||2.54||Price/Cash Per Share|
|Price/Free Cash Flow||-14.75||ROA||-43.21%||ROE||-50.12%||ROI|
|Current Ratio||20.83||Quick Ratio||Long Term Debt/Equity||Debt Ratio||0.05|
|Gross Margin||Operating Margin||-378.54%||Net Profit Margin||-378.3%||Dividend Payout Ratio|
|Cash From Financing Activities||117.28 M||Cash From Investing Activities||-40.16 M||Cash From Operating Activities||-22.71 M||Gross Profit|
|Net Profit||-61.33 M||Operating Profit||-61.38 M||Total Assets||253.27 M||Total Current Assets||247.4 M|
|Total Current Liabilities||11.88 M||Total Debt||1.68 M||Total Liabilities||34.89 M||Total Revenue||910 K|
|High 52 week||15.12||Low 52 week||5.22||Last close||10.27||Last change||2.6%|
|RSI||42.98||Average true range||0.54||Beta||1.89||Volume||427.11 K|
|Simple moving average 20 days||-2.05%||Simple moving average 50 days||-13.08%||Simple moving average 200 days||-15.07%|
|Performance Week||1.68%||Performance Month||-15.75%||Performance Quart||-18.3%||Performance Half||-22.43%|
|Performance Year||9.96%||Performance Year-to-date||66.72%||Volatility daily||2.82%||Volatility weekly||6.31%|
|Volatility monthly||12.93%||Volatility yearly||44.79%||Relative Volume||342.21%||Average Volume||648.55 K|
|New High||New Low|
2020-06-03 11:30:03 | Epizyme EPZM Down 4.4% Since Last Earnings Report: Can It Rebound?
2020-05-14 09:22:01 | Epizyme EPZM: Strong Industry, Solid Earnings Estimate Revisions
2020-05-07 10:51:02 | Allogene's ALLO Q1 Loss Widens Y/Y, Pipeline Progresses
2020-05-05 09:11:01 | Epizyme's EPZM Q1 Earnings Beat Estimates, Revenues Miss
2020-05-05 08:46:30 | Edited Transcript of EPZM earnings conference call or presentation 4-May-20 1:00pm GMT
2020-05-04 19:00:56 | Epizyme Inc EPZM Q1 2020 Earnings Call Transcript
2020-05-04 07:45:11 | Epizyme EPZM Reports Q1 Loss, Misses Revenue Estimates
2020-05-04 07:04:32 | Epizyme: Q1 Earnings Insights
2020-05-04 06:30:00 | Epizyme Reports Business Progress and First Quarter 2020 Financial Results
2020-04-27 12:32:04 | Earnings Preview: Epizyme EPZM Q1 Earnings Expected to Decline
2020-04-27 06:30:00 | Epizyme Announces Date of First Quarter 2020 Financial Results
2020-04-26 10:02:25 | Is Epizyme, Inc.'s NASDAQ:EPZM CEO Overpaid Relative To Its Peers?
2020-04-19 07:02:00 | 3 “Strong Buy” Biotech Stocks with FDA Approvals on the Horizon
2020-04-08 18:56:48 | Is Epizyme Inc EPZM A Good Stock To Buy?
2020-03-25 11:30:03 | Epizyme EPZM Down 24.9% Since Last Earnings Report: Can It Rebound?
2020-03-20 06:30:00 | Epizyme Appoints Jeffery Kutok, M.D., Ph.D., as Chief Scientific Officer
2020-03-04 18:36:20 | Edited Transcript of EPZM earnings conference call or presentation 24-Feb-20 1:30pm GMT
2020-02-25 12:09:02 | Analysts: 3 Healthcare Stocks to Buy on Coronavirus Weakness
2020-02-25 09:38:02 | Epizyme EPZM Q4 Earnings Miss Estimates, Revenues Beat
2020-02-25 09:28:02 | Are Options Traders Betting on a Big Move in Epizyme EPZM Stock?
2020-02-25 05:17:31 | Here are the Mass.-based firms hit hardest in Monday's stock rout
2020-02-24 07:45:12 | Epizyme EPZM Reports Q4 Loss, Tops Revenue Estimates
2020-02-24 06:30:00 | Epizyme, Inc. to Host Earnings Call
2020-02-23 18:38:25 | The Week Ahead In Biotech: Biopharma Earnings Pick Up Pace
2020-02-20 08:42:01 | Epizyme EPZM to Report Q4 Earnings: What's in the Cards?
2020-02-19 09:21:02 | Biotech Stock Roundup: INCY's Solid Q4 Results, EPZM & SGEN's Pipeline Updates
2020-02-12 06:55:00 | Investors Who Bought Epizyme NASDAQ:EPZM Shares Three Years Ago Are Now Up 81%
2020-02-06 17:50:10 | Epizyme EPZM Stock Sinks As Market Gains: What You Should Know
2020-02-05 11:52:05 | Steven Cohen Renews His Interest in Verastem
2020-01-31 17:50:10 | Epizyme EPZM Dips More Than Broader Markets: What You Should Know
2020-01-29 09:59:02 | Biotech Stock Roundup: EPZM Drug Gets FDA Nod, XLRN & HEPA Surge on Study Data
2020-01-24 12:00:05 | Are You Looking for a Top Momentum Pick? Why Epizyme EPZM is a Great Choice
2020-01-24 09:57:02 | Epizyme Gets FDA Nod for Lead Drug in Epithelioid Sarcoma
2020-01-24 05:52:07 | Epizyme's Tazemetostat Drug For Epithelioid Sarcoma Gets Accelerated FDA Approval
2020-01-23 18:07:33 | FDA approves local biotech's first rare-cancer drug
2020-01-23 09:34:02 | Axsome AXSM Completes Patient Randomization in TRD Study
2020-01-22 11:30:04 | Is Epizyme EPZM Outperforming Other Medical Stocks This Year?
2020-01-22 10:00:03 | Evoke Pharma's NDA Resubmission for Gimoti Gets FDA Acceptance
2020-01-22 08:57:01 | Is the Options Market Predicting a Spike in Epizyme EPZM Stock?
2020-01-21 09:26:02 | Puma Biotech's PBYI Breast Cancer Drug Nerlynx Aids Growth